Boston Scientific Corp Boston Scientific Corp [BSX-PA] has reported $322 million quarterly profit, an decrease of $182 million from the previous quarter, the company said in a filing to the SEC for the Q2 ended Jun 30, 2024.
Boston Scientific reported the quarterly diluted earnings per share (EPS) fell by -35.29 percent to $0.2 from $0.3 in the previous quarter.
Dollars in millions | Jun 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
|---|
Income Statement |
| Revenue | $4,120.0 | $14,240.0 | $3,527.0 | $3,599.0 |
| Operating Profit | $520.0 | $2,343.0 | $693.0 | $514.0 |
| Net Income | $322.0 | $1,592.0 | $504.0 | $270.0 |
| Net Cash | $2,006.0 | -$70.0 | $7.0 | -$506.0 |
| Gross Margin | $2,850.0 | $9,896.0 | $2,426.0 | $2,542.0 |
| Operating Margin | $0.0 | $0.0 | $0.0 | $0.0 |
| Profit as % of Revenues | 885.09 | 69.49 | 68.78 | 70.63 |
| Profit as % of Assets | 1.56 | 4.71 | 1.52 | 0.82 |
| Profit as % of Stockholder Equity | 1.56 | 8.15 | 2.63 | 1.46 |
| Return on Equity | 1.56 | 8.15 | 2.63 | 1.46 |
| Return on Assets | 0.87 | 4.53 | 1.48 | 0.80 |
| Turnover Ratio | 19.99 | 0.42 | 0.11 | 0.11 |
| EBITA | $733.0 | $0.0 | $0.0 | $0.0 |
Balance Sheet |
| Total Assets | $37,108.0 | $35,136.0 | $34,043.0 | $33,601.0 |
| Total Liabilities | $16,499.0 | $15,605.0 | $14,914.0 | $15,117.0 |
Cash Flow Statement |
| Operating Cash Flow | $977.0 | $2,503.0 | $1,546.0 | $848.0 |
| Investing Cash Flow | -$556.0 | -$2,574.0 | -$1,521.0 | -$1,324.0 |
| Financing Cash Flow | $1,593.0 | $5.0 | -$10.0 | -$26.0 |
Disclaimer:USinMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. Although care is taken to ensure accuracy, the article does not intend to replace user diligence in decisions of financial or legal implications.
![Boston Scientific Corp [BSX-PA] reports $322 million quarterly net profit](/_next/image?url=https%3A%2F%2F10kinfo-appdata.s3.us-west-2.amazonaws.com%2Fedgar0105%2FCompanyLogos%2FUS%2FBSX_i1.jpg&w=1200&q=75)